Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection

Respiratory Medicine

Volumn 102, Issue 11, 2008, Pages 1643-1653

  Steinkamp, Gratiana ^a   Schmitt Grohe, Sabina ^b   Döring, Gerd ^c   Staab, Doris ^d   Pfründer, Dietmar ^e   Beck, Gudrun ^e   Schubert, Ralf ^f   Zielen, Stefan ^f  

^a CF Centre Hamburg Altona and Clinical Research Hannover   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c Institute of General and Environmental Hygiene   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e PFIZER INC   (United States)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Azithromycin; Cystic fibrosis; Inflammation; Quality of life; Weekly dosage

Indexed keywords

ALGINIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; C REACTIVE PROTEIN; CEFTAZIDIME; COLISTIN; INTERLEUKIN 8; LIPOPOLYSACCHARIDE BINDING PROTEIN; MEROPENEM; PLACEBO; POLYMYXIN B; TOBRAMYCIN;

ADULT; ARTICLE; ASTHENIA; BRONCHOPNEUMONIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DYSPEPSIA; EXERCISE TOLERANCE; FEMALE; FEVER; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INFECTION; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINITIS; SIDE EFFECT; SPUTUM; THORAX DISEASE; UPPER ABDOMINAL PAIN;

ADULT; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 55549129249     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2008.03.009     Document Type: Article

References (31)

1. Stern M, Sens B, Wiedemann B, Busse O, Damm G, Wenzlaff P. Qualitätssicherung Mukoviszidose 2003, Überblick über den Gesundheitszustand der Patienten in Deutschland. 1 ed. Zentrum für Qualitätsmangement im Gesundheitswesen (Einrichtung der Ärztekammer Niedersachsen), 2004.
2. Worlitzsch D., Tarran R., Ulrich M., Schwab U., Cekici A., Meyer K.C., et al. Effects of mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 109 (2002) 317-325
3. Armstrong D.S., Grimwood K., Carlin J.B., Carzino R., Gutièrrez J.P., Hull J., et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 156 (1997) 1197-1204
4. Paul K., Rietschel E., Ballmann M., Griese M., Worlitzsch D., Shute J., et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 169 (2004) 719-725
5. Bell S.C., Senini S.L., and McCormack J.G. Macrolides in cystic fibrosis. Chron Respir Dis 2 (2005) 85-98
6. Nalca Y., Jänsch L., Bredenbruch F., Geffers R., Buer J., Häussler S., et al. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob Agents Chemother 50 (2006) 1680-1688
7. Nagino K., and Kobayashi H. Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginosa. Clin Microbiol Infect 3 (1997) 432-439
8. Jaffé A., Francis J., Rosenthal M., and Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 351 (1998) 420
9. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290 (2003) 1749-1756
10. Equi A., Balfour-Lynn I.M., Bush A., and Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360 (2002) 978-984
11. Wolter J., Seeney S., Bell S., Bowler S., Masel P., McCormack J., et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57 (2002) 212-216
12. Clement A., Tamalet A., Leroux E., Ravilly S., Fauroux B., Jais J.P., et al. Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax 61 10 (2006) 895-902
13. Southern K.W., Barker P.M., and Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev (2004) CD002203
14. Phaff S.J., Tiddens H.A., Verbrugh H.A., and Ott A. A macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis. J Antimicrob Chemother 57 (2006) 741-746
15. Wilms E.B., Touw D.J., and Heijerman H.G. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis. Ther Drug Monit 28 (2006) 219-225
16. Quanjer P.H., Stocks J., Polgar G., Wise M., Karlberg J., Borsboom G., et al. Compilation of reference values for lung function measurements in children. Eur Respir J 2 (1989) 184s-261s
17. Davies D.G., Parsek M.R., Pearson J.P., Iglewski B.H., Costerton J.W., Greenberg E.P., et al. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 280 (1998) 295-298
18. May T.B., and Chakrabarty A.M. Pseudomonas aeruginosa: genes and enzymes of alginate synthesis. Trends Microbiol 2 5 (1994) 151-157
19. Wenninger K., Aussage P., Wahn U., and Staab D. German Cystic Fibrosis Questionnaire study group, et al. The revised German Cystic Fibrosis Questionnaire: validation of a disease-specific health-related quality of life instrument. Qual Life Res 12 (2003) 77-85
20. Amsden G.W., and Gray C.L. Serum and WBC pharmacokinetics of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. J Antimicrob Chemother 47 (2001) 61-66
21. Wilms E.B., Touw D.J., and Heijerman. Pharmakokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients. J Cystic Fibros (2007 Jun 26)
22. McCormack J., Bell S., Senini S., Walmsley K., Patel K., Wainwright C., et al. Daily versus weekly azithromycin in cystic fibrosis patients. Eur Respir J 30 (2007) 487-495
23. Downey D.G., Brockbank S., Martin S.L., Ennis M., and Elborn J.S. The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol 42 3 (2007) 216-220
24. Levy H., Kalish L.A., Huntington I., Weller N., Gerard C., Silverman E.K., et al. Inflammatory markers of lung disease in adult patients with cystic fibrosis. Pediatr Pulmonol 42 3 (2007) 256-262
25. Cigana C., Nicolis E., Pasetto M., Assael B.M., and Melotti P. Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 350 (2006) 977-982
26. Schmitt-Grohé S., Naujoks C., Bargon J., Wagner T.O., Schubert R., Hippe V., et al. Interleukin-8 in whole blood and clinical status in cystic fibrosis. Cytokine 29 (2005) 18-23
27. Schmitt-Grohe S., Hippe V., Igel M., von Bergmann K., Posselt H.G., Krahl A., et al. Lipopolysaccharide binding protein, cytokine production in whole blood, and lipoproteins in cystic fibrosis. Pediatr Res 58 (2005) 903-907
28. Ichimiya T., Takeoka K., Hiramatsu K., Hirai K., Yamasaki T., Nasu M., et al. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 42 (1996) 186-191
29. Hansen C.R., Pressler T., Koch C., and Høiby N. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cystic Fibros 4 (2005) 35-40
30. Nguyen D., Emond M.J., Mayer-Hamblett N., Saiman L., Marshall B.C., Burns J.L., et al. Clinical response to Azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes. Pediatr Pulmonol 42 (2007) 533-541
31. Quittner A.L., Sweeny S., Watrous M., Munzenberger P., Bearss K., and Gibson Nitza A. Translation and linguistic validation of a disease-specific quality of life measure for cystic fibrosis. J Pediatr Psychol 25 (2000) 403-414